RSLS
ReShape Lifesciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 3
Downward Gap
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RSLS
Reshape Lifesciences Inc.
The premier physician-led weight loss and metabolic health solutions company
Healthcare Equipment and Supplies
01/02/2008
10/06/2016
NASDAQ Stock Exchange
17
12-31
Common stock
18 Technology Dr. , Suite 110, Irvine, California 92618
--
ReShape Lifesciences Inc. was incorporated on January 2, 2008 under the laws of the State of Delaware. The company is a commercial-stage medical device company that develops and sells Innovative Medical devices that treat obese and overweight people by promoting weight loss. The company's initial product line is the Obalon balloon system, which uses gas-filled intragastric balloons first swallowed to achieve progressive and sustained weight loss for obese patients.
Company Financials
EPS
RSLS has released its 2024 Q4 earnings. EPS was reported at -1.89, versus the expected 0.00, missing expectations. The chart below visualizes how RSLS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RSLS has released its 2024 Q4 earnings report, with revenue of 1.81M, reflecting a YoY change of -8.93%, and net profit of -1.76M, showing a YoY change of -3.71%. The Sankey diagram below clearly presents RSLS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
